New data raise profile of Truxima at EHA 2021

14 June 2021
celltrion-big

South Korean biosimilars specialist Celltrion Healthcare (Kosdaq: 068270) has presented new Phase IV data for Truxima (rituximab-abbs) at the annual meeting of the European Hematology Association (EHA).

The multi-country post-approval study is the first to investigate the safety and effectiveness of Truxima in people with diffuse large B-cell lymphoma (DLBCL) in a real-world setting.

The data presented at EHA show that at 30-months post-index, 67% of those taking Truxima as a first-line option had not experienced disease progression, with 74% overall survival.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars